To evaluate racial differences in survival outcomes for Black Americans (BA) and White Americans (WA) with multiple myeloma (MM) when matched for treatment and prognostic factors, highlighting the significance of equitable treatment access.
Key Findings:
After matching, survival outcomes for BA and WA were comparable, indicating no significant racial disparities, which suggests that treatment equity may mitigate these disparities.
Key prognostic factors were balanced between groups, including molecular risk and extent of disease, reinforcing the importance of matching.
BA were younger and had different baseline clinical characteristics, such as higher obesity rates, which may influence treatment outcomes.
Interpretation:
The study suggests that when Black Americans with multiple myeloma are matched for treatment and prognostic factors, their survival outcomes are similar to those of White Americans, challenging the notion that biological or genetic factors solely account for racial disparities in MM outcomes and emphasizing the role of equitable treatment.
Limitations:
The BA cohort was smaller, which may limit the generalizability of findings and the robustness of conclusions drawn.
Some clinical factors remained statistically significant post-matching, indicating potential residual confounding that should be considered in future research.
Conclusion:
Appropriate matching for treatment and prognostic factors can mitigate racial disparities in survival outcomes for Black Americans with multiple myeloma, emphasizing the critical importance of equitable treatment access in improving health outcomes.
by David E. Mery, Guido Tricot, Samer Al Hadidi, Yihao Zhan, Cody Ashby, Clyde Bailey, Eric R. Siegel, Daisy V. Alapat, Hongwei Xu, Sandra Mattox, Caroline Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Qing Yi, Robert Z. Orlowski, Frits van Rhee, John D. Shaughnessy, Fenghuang Zhan
